Cargando…

Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection

Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is an emerging zoonotic virus, which causes Coronavirus Disease 2019 (COVID-19). Entry of coronaviruses into the cell depends on binding of the viral spike (S) proteins to cellular receptors Angiotensin-converting enzyme 2 (ACE2). The viru...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Anupriya, Vaggu, Raghavendra Goud, Swain, Ramakrushna, Patnaik, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136399/
https://www.ncbi.nlm.nih.gov/pubmed/37106165
http://dx.doi.org/10.1007/s00284-023-03304-1
_version_ 1785032208506945536
author Sinha, Anupriya
Vaggu, Raghavendra Goud
Swain, Ramakrushna
Patnaik, Srinivas
author_facet Sinha, Anupriya
Vaggu, Raghavendra Goud
Swain, Ramakrushna
Patnaik, Srinivas
author_sort Sinha, Anupriya
collection PubMed
description Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is an emerging zoonotic virus, which causes Coronavirus Disease 2019 (COVID-19). Entry of coronaviruses into the cell depends on binding of the viral spike (S) proteins to cellular receptors Angiotensin-converting enzyme 2 (ACE2). The virus-mediated reduction of ACE2/Ang1-7 causes flooding of inflammatory cytokines. A similar scenario of hyper immunologic reaction has been witnessed in the context of Intestinal Inflammatory Diseases (IIDs) with the deregulation of ACE2. This review summarizes several IIDs that lead to such susceptible conditions. It discusses suitable mechanisms of how ACE2, being a crucial regulator of the Renin-Angiotensin System (RAS) signaling pathway, can affect the physiology of intestine as well as lungs, the primary site of SARS-CoV-2 infection. ACE2, as a SARS-CoV-2 receptor, establishes a critical link between COVID-19 and IIDs. Intercessional studies targeting the RAS signaling pathway in patients may provide a novel strategy for addressing the COVID-19 crisis. Hence, the modulation of these key RAS pathway members can be beneficial in both instances. However, it’s difficult to say how beneficial are the ACE inhibitors (ACEI)/ Angiotensin II type-1 receptor blockers (ARBs) during COVID-19. As a result, much more research is needed to better understand the relationship between the RAS and SARS-CoV-2 infection. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10136399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101363992023-04-28 Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection Sinha, Anupriya Vaggu, Raghavendra Goud Swain, Ramakrushna Patnaik, Srinivas Curr Microbiol Review Article Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is an emerging zoonotic virus, which causes Coronavirus Disease 2019 (COVID-19). Entry of coronaviruses into the cell depends on binding of the viral spike (S) proteins to cellular receptors Angiotensin-converting enzyme 2 (ACE2). The virus-mediated reduction of ACE2/Ang1-7 causes flooding of inflammatory cytokines. A similar scenario of hyper immunologic reaction has been witnessed in the context of Intestinal Inflammatory Diseases (IIDs) with the deregulation of ACE2. This review summarizes several IIDs that lead to such susceptible conditions. It discusses suitable mechanisms of how ACE2, being a crucial regulator of the Renin-Angiotensin System (RAS) signaling pathway, can affect the physiology of intestine as well as lungs, the primary site of SARS-CoV-2 infection. ACE2, as a SARS-CoV-2 receptor, establishes a critical link between COVID-19 and IIDs. Intercessional studies targeting the RAS signaling pathway in patients may provide a novel strategy for addressing the COVID-19 crisis. Hence, the modulation of these key RAS pathway members can be beneficial in both instances. However, it’s difficult to say how beneficial are the ACE inhibitors (ACEI)/ Angiotensin II type-1 receptor blockers (ARBs) during COVID-19. As a result, much more research is needed to better understand the relationship between the RAS and SARS-CoV-2 infection. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-04-27 2023 /pmc/articles/PMC10136399/ /pubmed/37106165 http://dx.doi.org/10.1007/s00284-023-03304-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Sinha, Anupriya
Vaggu, Raghavendra Goud
Swain, Ramakrushna
Patnaik, Srinivas
Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection
title Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection
title_full Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection
title_fullStr Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection
title_full_unstemmed Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection
title_short Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection
title_sort repurposing of ras-pathway mediated drugs for intestinal inflammation related diseases for treating sars-cov-2 infection
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136399/
https://www.ncbi.nlm.nih.gov/pubmed/37106165
http://dx.doi.org/10.1007/s00284-023-03304-1
work_keys_str_mv AT sinhaanupriya repurposingofraspathwaymediateddrugsforintestinalinflammationrelateddiseasesfortreatingsarscov2infection
AT vagguraghavendragoud repurposingofraspathwaymediateddrugsforintestinalinflammationrelateddiseasesfortreatingsarscov2infection
AT swainramakrushna repurposingofraspathwaymediateddrugsforintestinalinflammationrelateddiseasesfortreatingsarscov2infection
AT patnaiksrinivas repurposingofraspathwaymediateddrugsforintestinalinflammationrelateddiseasesfortreatingsarscov2infection